ISIS PHARMACEUTICAL
ISIS PHARMACEUTICAL operates in Diversified Metals & Mining.
ISIS PHARMACEUTICAL (ISI) - Net Assets
Latest net assets as of September 2024: €662.47 Million EUR
Based on the latest financial reports, ISIS PHARMACEUTICAL (ISI) has net assets worth €662.47 Million EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.08 Billion) and total liabilities (€2.42 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €662.47 Million |
| % of Total Assets | 21.5% |
| Annual Growth Rate | 21.4% |
| 5-Year Change | -77.05% |
| 10-Year Change | N/A |
| Growth Volatility | 128.69 |
ISIS PHARMACEUTICAL - Net Assets Trend (2016–2023)
This chart illustrates how ISIS PHARMACEUTICAL's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ISIS PHARMACEUTICAL (2016–2023)
The table below shows the annual net assets of ISIS PHARMACEUTICAL from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €386.69 Million | -32.50% |
| 2022-12-31 | €572.89 Million | -25.77% |
| 2021-12-31 | €771.74 Million | +3.83% |
| 2020-12-31 | €743.28 Million | -55.88% |
| 2019-12-31 | €1.68 Billion | +41.90% |
| 2018-12-31 | €1.19 Billion | +183.52% |
| 2017-12-31 | €418.72 Million | +320.55% |
| 2016-12-31 | €99.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ISIS PHARMACEUTICAL's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 61448300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.18 Billion | 564.44% |
| Total Equity | €386.69 Million | 100.00% |
ISIS PHARMACEUTICAL Competitors by Market Cap
The table below lists competitors of ISIS PHARMACEUTICAL ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ribbon Acquisition Corp Rights
NASDAQ:RIBBR
|
$639.28K |
|
JULIUS BAER GRP N (JGE.SG)
STU:JGE
|
$639.51K |
|
Fold Holdings, Inc. Warrant
NASDAQ:FLDDW
|
$640.41K |
|
ARCHER-DANIELS MID. - Dusseldorf Stock Exchang
DU:ADM
|
$640.54K |
|
Ovoca Gold PLC
IR:OVXA
|
$638.59K |
|
NEW YORK TIMES -A- (NYT.SG)
STU:NYT
|
$638.44K |
|
Gecina Nom
STU:GI6A
|
$638.28K |
|
Turbo Mech Bhd
KLSE:5167
|
$636.52K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ISIS PHARMACEUTICAL's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 572,887,000 to 386,686,000, a change of -186,201,000 (-32.5%).
- Net loss of 366,286,000 reduced equity.
- New share issuances of 49,442,000 increased equity.
- Other factors increased equity by 130,643,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-366.29 Million | -94.72% |
| Share Issuances | €49.44 Million | +12.79% |
| Other Changes | €130.64 Million | +33.79% |
| Total Change | €- | -32.50% |
Book Value vs Market Value Analysis
This analysis compares ISIS PHARMACEUTICAL's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.44x to 25.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.65 | €67.36 | x |
| 2018-12-31 | €7.60 | €67.36 | x |
| 2019-12-31 | €10.48 | €67.36 | x |
| 2020-12-31 | €5.30 | €67.36 | x |
| 2021-12-31 | €5.47 | €67.36 | x |
| 2022-12-31 | €4.03 | €67.36 | x |
| 2023-12-31 | €2.68 | €67.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ISIS PHARMACEUTICAL utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -94.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -46.50%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 7.73x
- Recent ROE (-94.72%) is below the historical average (-30.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -86.93% | -24.97% | 0.38x | 9.16x | €-96.51 Million |
| 2017 | -1.80% | -1.18% | 0.38x | 4.00x | €-39.06 Million |
| 2018 | 26.12% | 45.65% | 0.22x | 2.55x | €168.93 Million |
| 2019 | 20.00% | 26.20% | 0.35x | 2.20x | €147.04 Million |
| 2020 | -59.77% | -60.92% | 0.31x | 3.22x | €-518.59 Million |
| 2021 | -3.71% | -3.53% | 0.31x | 3.38x | €-105.77 Million |
| 2022 | -47.08% | -45.92% | 0.23x | 4.42x | €-327.01 Million |
| 2023 | -94.72% | -46.50% | 0.26x | 7.73x | €-404.95 Million |
Industry Comparison
This section compares ISIS PHARMACEUTICAL's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ISIS PHARMACEUTICAL (ISI) | €662.47 Million | -86.93% | 3.65x | $638.61K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |